Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

AEterna Zentaris Inc. buy melinda

AEterna Zentaris Inc.
Start price
€82.50
02.12.18 / 50%
Target price
€87.50
04.12.18
Performance (%)
6.06%
End price
€87.50
04.12.18
Summary
This prediction ended on 04.12.18 with a price of €87.50. The BUY prediction by melinda finished with a performance of 6.06%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
AEterna Zentaris Inc. 1.081% 1.081% -28.077% -91.762%
iShares Core DAX® -0.922% -1.993% 13.399% 16.075%
iShares Nasdaq 100 0.371% -0.868% 41.541% 46.938%
iShares Nikkei 225® 2.224% -5.187% 20.497% 4.643%
iShares S&P 500 -0.026% -0.918% 30.410% 42.418%

Comments by melinda for this prediction

In the thread AEterna Zentaris Inc. diskutieren
Prediction Buy
Perf. (%) 6.06%
Target price 3.500
Change
Ends at 04.12.18

ASTRAZENECA



Malgré les résultats décevants de l'étude, la société a réintroduit la NDA pour Macrilen en juin de cette année et le verdict est maintenant attendu.



Aeterna Zentaris



Zeneca: Acalabrutinib obtient le label de traitement crucial de la FDA

2017-08-01 03:14 ET

Le médecin majoritaire britannique AstraZeneca plc. ( AZN.L , AZN ) et le Centre pour la recherche et le développement dans l' hématologie Acerta Pharma a annoncé mardi , que la Food and Drug Administration des États-Unis a remporté la thérapie révolutionnaire ou le nom BTD pour acalabrutinib. Le BTD est destiné au traitement des patients présentant un revêtement membranaire de lymphome ou MCL ayant reçu au moins un traitement antérieur.



melinda 
0
Report Share
02.12.18
Prediction Buy
Perf. (%) 6.06%
Target price 3.500
Change
Ends at 04.12.18

(Zielkurs erreicht)

melinda 
0
Report Share
04.12.18

Stopped prediction by melinda for AEterna Zentaris Inc.

buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€12.50
12.03.20
€37.50
04.11.21
8.80%
05.11.21

melinda 
12.03.20 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€89.30
03.02.19
€112.75
05.08.19
-42.42%
05.08.19

melinda 
18.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€76.25
02.12.18
€87.50
03.12.18
0.00%
03.12.18

melinda 
18.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€49.30
01.02.18
€85.69
01.08.18
-18.59%
01.08.18

melinda 
18.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€44.20
01.08.17
€78.93
01.02.18
10.20%
01.02.18

melinda 
14.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€49.00
01.08.17
€87.50
01.02.18
10.20%
01.02.18

melinda 
14.08.19 50%
sell
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€69.99
20.07.17
€50.00
28.07.17
0.00%
28.07.17

melinda 
14.08.19 50%
sell
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€63.13
20.07.17
€45.10
28.07.17
-24.63%
28.07.17

melinda 
14.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€27.00
26.05.17
€50.00
19.07.17
110.19%
19.07.17

melinda 
14.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€24.36
26.05.17
€45.10
19.07.17
110.19%
19.07.17

melinda 
14.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€19.39
17.05.17
€24.81
25.05.17
10.05%
25.05.17

melinda 
14.08.19 50%
buy
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€13,500
15.07.10
€30,000
28.09.10
7.78%
28.09.10

melinda 
14.08.19 50%